The diagnostic and therapeutic challenge of atrial flutter in children: a case report
Italian Journal of Pediatrics volume 49, Article number: 137 (2023)
Palpitations represent a common cause for consultation in the pediatric Emergency Department (ED). Unlike adults, palpitations in children are less frequently dependent from the heart, recognizing other causes.
A 11-year-old male came to our pediatric ED for epigastric pain, vomiting and palpitations. During the previous 6 month the patient was affected by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus). Electrocardiogram (ECG) revealed supraventricular tachycardia. Therefore, adenosine was administered unsuccessfully. The administration of adenosine, however, allowed us to make diagnosis of atypical atrial flutter. Multiple attempts at both electrical cardioversion, transesophageal atrial overdrive, and drug monotherapy were unsuccessful in our patient. Consequently, a triple therapy with amiodarone, flecainide, and beta-blocker was gradually designed to control the arrhythmic pattern with the restoration of a left upper atrial rhythm. There was not any evidence of sinus rhythm in the patient clinical history.
The present study underlines the rarity of this type of dysrhythmia in childhood and the difficulties in diagnosis and management, above all in a patient who has never showed sinus rhythm. Raising awareness of all available treatment options is essential for a better management of dysrhythmia in children
Palpitations represent a common cause for consultation in the pediatric Emergency Department (ED). Unlike adults, palpitations in children are less frequently dependent from the heart, recognizing other causes (anxiety, fear, exercise or fever). The overall incidence of dysrhythmias is 55.1 per 100,000 pediatric ED visits . Nevertheless, the pediatric ED physician should be able to determine whether child requires immediate examination and referral to a cardiologist [2, 3]. Sacchetti et al.  conducted a retrospective review of cardiac dysrhythmias in children presenting to the ED, and revealed that sinus tachycardia was the most commonly reported dysrhythmia (50%), followed by supraventricular tachycardia (13%), nonspecific dysrhythmias (10.6%), bradycardia (6%), and atrial fibrillation (4.6%).
Here we report the case of a 11-year-old boy with structurally normal heart and a history of previous SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection, admitted to the pediatric ED for tachycardia determined by a rare cause. Furthermore, it is emphasized that lack of evidence-based therapies makes management of dysrhythmias particularly difficult and complex in childhood.
A 11-year-old male presented to the pediatric ED with epigastric pain, vomiting and palpitations.
Patient’s medical history included a pauci-symptomatic SARS-CoV-2 infection in the previous six months, confirmed by the finding of Immunoglobulin (Ig) G for SARS-CoV-2 in the absence of IgM, and was negative for syncope or other cardiac manifestations. There was no familiarity for congenital heart disease or sudden cardiac death.
At admission general conditions were not so poor, with body temperature of 36.5 °C, oxygen saturation in room air of 99%, respiratory rate of 15 breaths/min, systemic blood pressure of 95/65 mmHg, except for a heart rate (HR) of 250 beats/min. The anthropometric parameters were: weight 32 kg, height 135 cm, body surface area 1.095 m2.
Electrocardiogram (ECG) revealed supraventricular tachycardia with a narrow QRS; atrial rate (AR) was equal to ventricular (VR) and was 230 b/min. Echocardiography revealed mild depressed biventricular function with ejection fraction (EF) of 53%, left atrial dilatation and moderate mitral regurgitation.
Adenosine was administered twice: first dose 0,1 mg/kg; second dose 0,2 mg/kg - both ineffective.
The administration of adenosine (0,1 mg/kg), however, allowed us to make diagnosis of atypical atrial flutter (AFL) (Fig. 1).
Therefore, therapy with intravenous flecainide (2 mg/kg in 15 min) was attempted with no response.
Continuous intravenous amiodarone (300 mg/m2/d) was started leading to unsatisfactory heart rate control and, above all, unsuccessful rhythm control.
Due to the persistence of AFL, synchronized direct current cardioversion (first shock at 75 J and second one at 100 J) was performed without success.
Therefore, oral propranolol (1 mg/kg/d) was added to therapy with a better heart rate control but not as expected. After 24 h intravenous amiodarone was discontinued and oral amiodaron (150 mg/m2/d) was started.
In the following days, further attempts at both synchronized direct current cardioversion and transesophageal atrial pacing were ineffective to stop dysrhythmia.
Therefore, propranolol posology was increased to 1.5 mg/kg/d and oral flecainide (4.7 mg/d) was introduced. The result was represented by a gradual reduction of ventricular response and, after two days of this therapy, ECG demonstrated the dysrhythmia disorganization with the appearance of polyfocal atrial tachycardia.
Due to the persistence of protracted phases of ectopic atrial tachycardia, flecainide was further increased to 5 mg/d with progressive reduction of the arrhythmic pattern.
During the hospitalization the patient was monitored using continuous ECG, several Holter ECG and 12-lead ECG more than once a day, as well as echocardiographic evaluation and periodical biochemistry (the latter always within normal range).
Combined therapy with amiodarone (150 mg/m2/d), propranolol (1.5 mg/kg/d) and flecainide (5 mg/Kg/d) was able to ensure satisfactory heart rate control, but without restoring sinus rhythm and appearance of stable upper left atrial rhythm with HR of 85 beats/min (Figs. 2 and 3).
Echocardiography also showed normalization of ventricular function and atrial size. Mild mitral regurgitation persisted due to kneeling of the anterior valve leaflet.
In consideration of evident clinical and echocardiographic improvement, the patient was discharged and underwent follow-up.
After one month of follow-up, to date, this therapy continues to show satisfactory results in terms of clinical conditions and control of dysrhythmia.
As further confirmation, we asked the parents for a previous ECG of the child and we learned that he already had a baseline left upper atrial rhythm two months before the arrhythmic event.
Subsequent diagnostic investigations, such as cardiac magnetic resonance and endomyocardial biopsy, may be useful to define the nature of this rare case of adolescent atrial flutter and its future therapeutic management.
Discussion and conclusions
Atrial flutter (AFL) represents a rare dysrhythmia in children; it is characterized by fast and regular atrial activity (240–500 beats per minute) usually caused by macro-reentry circuit within the atrial wall . It is frequently associated with 2:1 atrioventricular (AV) conduction. Vagal stimulation, adenosine, or beta blockers can increase the degree of AV block and unmask atrial waves on the ECG that are often enough for diagnosis [5,6,7,8,9].
AFL is divided, also in childhood, into two categories: typical and atypical forms .
Atypical atrial flutter includes a broad spectrum of other macro-reentrant tachycardias in which the wave front does not travel around the tricuspid annulus .
In our case, an atypical AFL was diagnosed with probable origin in the left atrium .
Beyond this period, it is mainly found in children with congenital heart defects, especially after cardiac surgery performed within atria, or in case of systemic disease with immaturity of the conduction system of the heart [6, 7].
In a multicenter study including 380 patients with atrial flutter aged 1 to 25 years, only 8% had a structurally normal heart .
This low incidence precludes large pediatric studies of these dysrhythmias with a lack of evidence-based recommendations for management, especially in children and adolescents.
Recommended treatment to restore neonatal sinus rhythm includes electrical cardioversion, transesophageal atrial pacing, or antiarrhythmic drugs .
In children and adolescents, depending on the clinical presentation and antiarrhythmic drug efficacy, additional treatments are electrophysiological study and catheter ablation of the AFL substrate .
The recommended drugs are digoxin with the addition of flecainide or amiodarone in case of therapeutic failure. Although they take some time to restore sinus rhythm, they may be tried in a stable patient .
Digoxin has been widely used as a positive inotropic agent in patients with systolic heart failure and as a negative chronotropic agent in patients with AFL .
In our case, it was previously avoided because its use might be potentially dangerous during electrical cardioversion . Multiple attempts at both electrical cardioversion, transesophageal atrial overdrive, and drug monotherapy were unsuccessful in our patient. Consequently, a triple therapy with amiodarone, flecainide, and beta-blocker was gradually and empirically designed to control the arrhythmic pattern. In our center, we prefer to exploit the synergistic effect of drugs with different mechanisms of action rather than increasing the dosages of single drugs up to the upper limits of the therapeutic range.
In addition to the clinical and echocardiographic improvement, the efficacy was further confirmed by the restoration of the basal rhythm, pre-existing to the arrhythmic event, even if not originating from the sinus node.
Ectopic atrial rhythm (EAR) could be a normal characteristic in healthy children ; this pattern could also be associated with cardiac tissue alterations due to surgery (like cardiopathies) or myocardial changes (like Fabry’s disease or left ventricular noncompaction). In our case there was no evidence of tissue damage due to surgical fibrosis or myocardial abnormalities. Otherwise, the patient was affected by Sars-CoV-2 during the previous 6 months and his ECGs over this period always showed stable left upper atrial rhythm; there was no availability of previous ECGs prior to the infection. Common cardiac manifestations in SARS-CoV-2 infection and Multisystem Inflammatory Syndrome in Children are ventricular disfunction, coronary anomalies and a wide spectrum of rhythm abnormalities .
In this clinical case, SARS-CoV-2 infection might be the trigger for patient’s persistent EAR as well as for the atrial atypical flutter episode.
It is now known that atrial flutter most often occurs as a single episode without late recurrence. Therefore, long-term prophylaxis is not routinely recommended .
Recently, the role of endomyocardial biopsy in revealing underlying cardiac disease, has been highlighted in a significant number of patients with presumed “lone AFL”.
Furthermore, the use of cardiac magnetic resonance and possible genetic tests is recommended in order to set a disease-specific treatment .
For this reason, these investigations represent the next steps in our patient’s diagnostic work-up.
Both the results of the diagnostic investigations and the response to drug therapy will guide us in the future therapeutic management of the patient.
The present study underlines the rarity of this type of dysrhythmia in childhood and the difficulty of its diagnosis and management. F waves may be difficult to see initially on ECG due to accelerated ventricular response: in our case, what at first appeared to be supraventricular tachycardia, after the use of adenosine that slowed atrial frequency, turned out to be an atrial flutter.
Therefore, raising awareness of all available treatment options is essential for better management of dysrhythmia in children.
Further studies on larger group of patients beyond the neonatal period are essential to establish the most appropriate and effective combinations of drugs to recommend in the pediatric age.
All data generated or analyzed during this study are included in this published article.
Atypical atrial flutter
Ectopic Atrial Rhythm
Severe Acute Respiratory Syndrome Coronavirus 2
Rivera RF, Chambers P, Ceresnak SR. Evaluation of children with palpitation. Clin Pediatr Emerg Med. 2011;12:278–9.
De Nigris A, Pepe A, Di Nardo G, Giannattasio A, Pagano A, D’Anna C, et al. Brugada Pattern in a child with severe SARS-CoV-2 related multisystem inflammatory syndrome. Pediatr Rep. 2021;13:504–10.
Di Marco GM, De Nigris A, Pepe A, Pagano A, Di Nardo G, Tipo V. Ivabradine-flecainide as breakthrough drug combination for congenital junctional ectopic tachycardia: a Case Report and Literature Review. Pediatr Rep. 2021;13:624–31.
Sacchetti A, Moyer V, Baricella R, Cameron J, Moakes ME. Primary cardiac arrhythmias in children. Pediatr Emerg Care. 1999;15:95–8.
Krapp M, Kohl T, Simpson JM, Sharland GK, Katalinic A, Gembruch U. Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia. Heart. 2003;89:913–17.
Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15:1337–82.
Garson A Jr, Bink-Boelkens M, Hesslein PS, Hordof AJ, Keane JF, Neches WH, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol. 1985;6:871–8.
Mendelsohn A, Dick M, Serwer GA. Natural history of isolated atrial flutter in infancy. J Pediatr. 1991;119:386–91.
Drago F, Tamborrino PP. Atrial flutter in Pediatric Patients. Card Electrophysiol Clin. 2022;14:495–500.
Alboni P, Brignole M, Disertori M, Lunati M, Oreto G, Salerno JA, et al. [Cardiac arrhythmia: terminology update]. G Ital Cardiol. 1999;29:805–9.
Doiny D, Merino JL. Atrial flutter: common and main atypical forms. An article from the e-journal of the ESC Council for Cardiology. 2013. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms. Accessed December 4, 2022.
Texter KM, Kertesz NJ, Friedman RA, Fenrich AL Jr. Atrial flutter in infants. J Am Coll Cardiol. 2006;48:1040–6.
Casey FA, McCrindle BW, Hamilton RM, Gow RM. Neonatal atrial flutter: significant early morbidity and excellent long-term prognosis. Am Heart J. 1997;133:302–6.
Philip Saul J, Kanter RJ, WRITING COMMITTEE, Abrams D, Asirvatham S, Bar-Cohen Y, et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: developed in partnership with the Pediatric and congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and congenital cardiology (AEPC). Heart Rhythm. 2016;13:e251–89.
Smith TW, Digitalis. Mechanisms of action and clinical use. N Engl J Med. 1988;318:358–65.
Mina GS, Acharya M, Shepherd T, Gobrial G, Tekeste M, Watti H. Digoxin is Associated with increased shock events and electrical Storms in patients with Implantable Cardioverter defibrillators. J Cardiovasc Pharmacol Ther. 2018;23:142–48.
Drago F, Battipaglia I, Di Mambro C. Neonatal and Pediatric Arrhythmias: clinical and Electrocardiographic aspects. Card Electrophysiol Clin. 2018;10:397–412.
Abadir S, Fournier A, Dubuc M, Khairy P. Atrial flutter and fibrillation in the young patient without congenital heart disease. Prog Pediatr Cardiol. 2013;35:41–8.
Verma A, Macle L, Cox J, Skanes AC, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol. 2011;27:60–6.
Dieks JK, Klehs S, Müller MJ, Paul T, Krause U. Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia. Heart Rhythm. 2016;13:1297–302.
Ethics approval and consent to participate
This study was conducted according to the Declaration of Helsinki regarding the Ethical Principles for Medical Research Involving Human Subjects. To keep the privacy of participants’, names were not used and the data confidentiality was maintained at all levels of the study. Ethical approval was not requested from the Santobono-Pausilipon Ethics Committee for this study, due to the nature of the article which is a case report.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and accompanying images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
De Nigris, A., Arenella, M., Di Nardo, G. et al. The diagnostic and therapeutic challenge of atrial flutter in children: a case report. Ital J Pediatr 49, 137 (2023). https://doi.org/10.1186/s13052-023-01542-4